Multimodal Immune Cell Profiling

C57BL/6J, B6.129(Cg)-Ccr2^tm2.1Ifc/J (CCR2-RFP), B6.Cg-Tg(Itgax-Venus)1Mnz/J (CD11c-YFP), B6(Cg)-Tyr^c−2J/J (B6 albino), B6.Cg-Zbtb46^{tm4.1(HBEGF)MnzTyrc−2J}/J (Zbtb46-DTR), B6.129P2(C)-Ccr7^tm1Rfor/J (CCR7.KO), B6.129S1-Il12^btm1Jm/J (IL-12p40.KO), and B6.129S4-Ccr2^tm1Ifc/J (CCR2.KO) mouse strains were obtained from The Jackson Laboratory. CD45.1⁺ B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II), CD45.1⁺ C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I), and B6.SJL-Ptprc^aPepc^b/BoyCrl (CD45.1⁺) were obtained either from donating investigators (Dr. Pamela J. Fink, University of Washington) or Charles River. CD11c-YFP animals were crossed with B6 albino mice to homozygosity, and next crossed to CCR2-RFP mice to generate a CD11c-YFP x CCR2-RFP^Hetrozygous dual reporter mice. CCR2-DTR mice were obtained from donating investigators (Dr. Steven F. Ziegler, Benaroya Research Institute) and with approval from the originating investigators (Drs. Tobias M. Hohl and Eric G. Pamer, Memorial Sloan-Kettering Cancer Center) (95 (link)). 6–10 week-old male and female mice were kept in specific pathogen–free conditions at an Association for Assessment and Accreditation of Laboratory Animal Care–accredited animal facility at the University of Washington, South Lake Union campus. All procedures were approved by the University of Washington Institutional Animal Care and Use Committee.